abstract: Allogeneic stem cell transplantations represent perfect example of immunotherapy. Its positive aspects are due to the graft versus tumor effect. Unfortunately, this therapeutic advantage is usually associated with graft versus host effects. While the mechanism of these two graft reactions remain unclear, this is possible to modulate these immunologic effects. The type of conditioning regimen, the source of donor and the use of donor cells after the transplantation may influence the toxicity and the tumor response, leading to a better optimization of the procedure. This paper is presenting all the parameters which may contribute to improve allogeneic stem cell transplantations.
authors.affiliation: Hématologie clinique et transplantation, GH Henri-Mondor, Créteil, France.
authors.forename: Flore Sicre
authors.initials: FS
authors.lastname: de Fontbrune
authors.affiliation: Service de thérapie cellulaire et d'hématologie clinique adulte, CHU Clermont-Ferrand, site Estaing, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France.
authors.forename: Doriane
authors.initials: D
authors.lastname: Cavalieri
authors.affiliation: Service d'hématologie, greffe de moelle, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Leclerc
authors.affiliation: Service d'hématologie, greffe de moelle, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Beckerich
authors.affiliation: Service d'hématologie, greffe de moelle, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Maury
authors.affiliation: Hématologie clinique et transplantation, GH Henri-Mondor, Créteil, France.
authors.forename: Régis Peffault
authors.initials: RP
authors.lastname: de Latour
authors.affiliation: Service d'hématologie clinique, hôpital de la Pitié-Salpêtrière (AP-HP) ; Centre d'immunologie et des maladies infectieuses (CIMI-Paris), université Sorbonne, UPMC, université Paris 06, INSERM U1135, CNRS ERL8255, Paris, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: N-Guyen
authors.affiliation: Service de thérapie cellulaire et d'hématologie clinique adulte, CHU Clermont-Ferrand, site Estaing, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
mesh_terms: D006087:Graft vs Host Reaction / Q000276:immunology; D020350:Graft vs Tumor Effect / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006648:Histocompatibility / Q000235:genetics / Q000276:immunology; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D006680:HLA Antigens
keywords: Allogeneic transplantation; Allogreffe de moelle; HLA typing; Immunotherapy; Immunothérapie; Typage HLA